Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Alzheimer'S & Dementia (New York, N. Y.)|February 22, 2021
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's diseaseJennifer A Zimmer, Sergey Shcherbinin, Michael D Devous, et al.
JAMA Neurology|February 15, 2021
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical TrialsMing Lu, Michael J Pontecorvo, Michael D Devous, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 10, 2026
Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's diseasePaul Ardayfio, Garrett R Mullins, Rashna Khanna, et al.
JAMA|July 17, 2023
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical TrialJohn R Sims, Jennifer A Zimmer, Cynthia D Evans, et al.
The Journal of Prevention of Alzheimer'S Disease|December 2, 2025
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extensionJennifer A Zimmer, John R Sims, Cynthia D Evans, et al.
JAMA Neurology|March 10, 2025
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical TrialsJennifer A Zimmer, Paul Ardayfio, Hong Wang, et al.
JAMA Neurology|November 26, 2019
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical TrialsAlette M Wessels, Pierre N Tariot, Jennifer A Zimmer, et al.
Journal of Alzheimer'S Disease Reports|March 4, 2022
Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical SpeciesBrian A Willis, Stephen L Lowe, Scott A Monk, et al.
Journal of Clinical Medicine|April 30, 2021
Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) StudyJames A Hendrix, David C Airey, Angela Britton, et al.
Pageof 2